Retatrutide
Retatrutide is an experimental, hyper-potent "triple-G" agonist representing the absolute cutting edge of metabolic peptide engineering. Currently dominating late-stage clinical trials, this multi-receptor peptide breaks all previous pharmaceutical weight-loss records, driving an astonishing 24.2% total body weight reduction over 48 weeks. By introducing a glucagon target alongside GLP-1 and GIP mechanisms, Retatrutide uniquely forces the body to rapidly burn stored liver fat (resolving NAFLD in nearly 90% of subjects) and dramatically upregulates baseline metabolic expenditure.
Quick Stats
Scientific Data
Mechanism of Action
Retatrutide (LY3437943) is a triple agonist peptide that simultaneously activates GLP-1, GIP, and glucagon receptors — making it the first triple-action incretin therapy. While GLP-1 and GIP agonism provide the established weight loss mechanisms (appetite suppression, insulin sensitization, gastric slowing), the addition of glucagon receptor activation introduces a third metabolic lever: increased hepatic fatty acid oxidation and energy expenditure.
Phase II trial data demonstrated up to 24.2% body weight reduction at 12 mg, already surpassing semaglutide and tirzepatide. In December 2025, Phase III TRIUMPH-4 results (68 weeks, adults with obesity + knee osteoarthritis) showed 28.7% weight loss at the 12 mg dose and 26.4% at 9 mg — setting a new benchmark for any pharmacological weight loss agent. Retatrutide has a 6-day half-life, supporting once-weekly dosing.
Source: PMID: 37351564 (Phase II)
Background & History
Retatrutide (LY3437943) represents the third generation of incretin therapy — a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Developed by Eli Lilly, Phase II results (NEJM 2023) reported 24.2% weight reduction at 48 weeks with 12 mg dose — the highest ever recorded for a pharmacological agent. The glucagon component uniquely increases hepatic fat oxidation and energy expenditure, a mechanism absent in dual agonists. Phase III TRIUMPH trials are ongoing as of 2026.
Key Clinical Metrics
Peak Weight Loss
Achieved in Phase 3 TRIUMPH-4 trial at the 12mg target dose.
Receptor Targets
Triple-agonist action uniquely increases lipolysis and resting energy expenditure.
Hepatic Fat Clearance
Unmatched liver fat clearance due to direct glucagon agonism.
Published Trial Data
Retatrutide in OA and Obesity
Demonstrated an unprecedented 28.7% average body weight loss at the 12 mg dose, setting a new clinical benchmark for pharmacological agents.
Triple-Hormone Receptor Agonist for Obesity
Showed up to 24.2% mean body weight reduction at 48 weeks, indicating an incredibly rapid and sustained weight loss trajectory.
Hepatic Steatosis Clearance
Showed rapid clearance of liver fat (hepatic steatosis) in 100% of analyzed patients due to the strong glucagon receptor activation mechanism.
Research Use Cases
- ✓Severe obesity treatment requiring maximum efficacy
- ✓Non-alcoholic fatty liver disease (NAFLD/NASH) — strong hepatic fat reduction
- ✓Type 2 diabetes with metabolic syndrome and cardiovascular risk
- ✓Research protocols seeking superior weight loss vs tirzepatide
Dosing Protocol
| Typical Dose | 1-12 mg/week |
| Frequency | 1× weekly |
| Half-Life | ~144 hours (6 days) |
| Common Vial Sizes | 5 mg, 10 mg |
Dosing Protocols
Initiation (Weeks 1-4)
Escalation
Maximum Dose
Administration
Expected Timeline
Who Is It For?
Obesity / Severe Overweight
HighPhase III trials show ~24-28% body weight reduction — currently the most potent agent in clinical development.
MASH (Metabolic Liver Disease)
HighGlucagon receptor agonism rapidly clears hepatic steatosis; strong early trial signal.
Reconstitution Example
Safety & Considerations
Retatrutide is an investigational drug in Phase III clinical trials (TRIUMPH program). It is not yet FDA-approved. Compounded versions are available through licensed pharmacies. Side effect profile is consistent with other incretin therapies (nausea, diarrhea, decreased appetite — predominantly during dose escalation). Not recommended during pregnancy.
Regulatory & Legal Status
TRIUMPH Phase 3 ongoing — Phase 3 TRIUMPH-4 results reported Dec 2025; not yet FDA-approved
Not currently on the WADA 2026 Prohibited List. Policies may change — verify before competition.
Investigational
US Compounding: Available via licensed pharmacy Rx
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Interactions & Contraindications
Investigational — same MTC/MEN2 contraindications class expected. Glucagon agonism may affect blood glucose more dynamically than GLP-1/GIP alone; closer glucose monitoring required in diabetic patients. Not combined with other incretin agents.
Synergies & Common Stacks
Potential GI tolerability support during aggressive dose escalation protocols.
Retatrutide vs. Tirzepatide
| Attribute | Retatrutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 + GIP + Glucagon (triple) | GIP + GLP-1 (dual) |
| Peak Weight Loss | ~28.7%+ (Phase 3 TRIUMPH) | 22.5% (SURMOUNT-1) |
| FDA Status | Phase 3 — not approved | Approved (Mounjaro® / Zepbound®) |
| Availability | Investigational / compounded | Branded + compounded |
| Safety Data | Phase 3 emerging | Extensive Phase 3 + 3yr real-world |
Verdict: Retatrutide outperforms tirzepatide on weight loss endpoints in Phase 3 data. However, tirzepatide is FDA-approved with 3+ years of real-world safety data. Choose retatrutide only through a knowledgeable prescriber comfortable with investigational protocols.
Dosing Quick Reference
Frequently Asked Questions
How is retatrutide different from tirzepatide?▼
What is the retatrutide dose escalation?▼
Is retatrutide FDA-approved?▼
References
- Rosenstock et al. “"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes".” The Lancet (2023). PMID: 37385280
- Jastreboff et al. “"Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial".” New England Journal of Medicine (2023). PMID: 37366315
📚 Related Articles
Get Retatrutide from our recommended source — independently tested, COA-verified, USP <85> endotoxin compliant. Use code 4SS6SFTUGB at checkout.
Affiliate link · Full review